Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modiWed eVectors that carry a tumor-speciWc antigen receptor

Cancer Immunology, Immunotherapy

Volumn 61, Issue 9, 2012, Pages 1451-1461

  Sahm, Christiane ^a   Schönfeld, Kurt ^a   Wels, Winfried S ^a  

^a INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

Author keywords

Chimeric antigen receptor; EpCAM; Interleukin 15; Lentiviral vector; Natural killer cells; ScFv antibody

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; EPITHELIAL CELL ADHESION MOLECULE; INTERLEUKIN 15; INTERLEUKIN 2; LENTIVIRUS VECTOR; LYMPHOCYTE ANTIGEN RECEPTOR; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CELL ACTIVATION; CELL GROWTH; CELL KILLING; CELL LINE; CELL PROLIFERATION; CELL STRAIN NK 92; CELL STRAIN NKL; CONTROLLED STUDY; DNA MODIFICATION; EFFECTOR CELL; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING;

ANIMALS; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DNA, COMPLEMENTARY; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-15; INTERLEUKIN-2; K562 CELLS; KILLER CELLS, NATURAL; LEUKEMIA, ERYTHROBLASTIC, ACUTE; MELANOMA; MICE; RECEPTORS, ANTIGEN; RNA, MESSENGER;

EID: 84866541747     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1212-x     Document Type: Article

References (40)

1. Gross G, Waks T, Eshhar Z (1989) Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type speciWcity. Proc Natl Acad Sci USA 86:10024-10028 (Pubitemid 20030768)
2. Uherek C, Groner B, Wels W (2001) Chimeric antigen receptors for the retargeting of cytotoxic eVector cells. J Hematother Stem Cell Res 10:523-534. doi:10.1089/15258160152509136 (Pubitemid 32756191)
3. Hombach A, Abken H (2007) Costimulation tunes tumor-speciWc activation of redirected T cells in adoptive immunotherapy. Cancer Immunol Immunother 56:731-737 (Pubitemid 46348741)
4. Ngo MC, Rooney CM, Howard JM, Heslop HE (2011) Ex vivo gene transfer for improved adoptive immunotherapy of cancer. Hum Mol Genet 20:R93-R99
5. Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011) Chimeric antigen receptor-modiWed T cells in chronic lymphoid leukemia. N Engl J Med 365:725-733. doi:10.1056/NEJMoa1103849
6. Uherek C, Tonn T, Uherek B, Becker S, Schnierle B, Klingemann HG, Wels W (2002) Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in eYcient and selective tumor cell destruction. Blood 100:1265-1273 (Pubitemid 34864281)
7. Wels W, Biburger M, Müller T, Dälken B, Giesübel U, Tonn T, Uherek C (2004) Recombinant immunotoxins and retargeted killer cells: employing engineered antibody fragments for tumor-speciWc targeting of cytotoxic eVectors. Cancer Immunol Immunother 53:217-226. doi:10.1007/s00262-003-0482-8 (Pubitemid 38328044)
8. Imai C, Iwamoto S, Campana D (2005) Genetic modiWcation of primary natural killer cells overcomes inhibitory signals and induces speciWc killing of leukemic cells. Blood 106:376-383 (Pubitemid 40967217)
9. Pegram HJ, Kershaw MH, Darcy PK (2009) Genetic modiWcation of natural killer cells for adoptive cellular immunotherapy. Immunotherapy 1:623-630. doi:10.2217/imt.09.36
10. Lanier LL (2008) Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 9:495-502. doi:10.1038/ni1581 (Pubitemid 351560518)
11. Klingemann HG (2005) Natural killer cell-based immunotherapeutic strategies. Cytotherapy 7:16-22
12. Tonn T, Becker S, Esser R, Schwabe D, Seifried E (2001) Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res 10:535-544. doi:10.1089/15258160152509145 (Pubitemid 32756192)
13. Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J, Klingemann H (2008) Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy 10:625-632. doi:10.1080/14653240802301872
14. Tavri S, Jha P, Meier R, Henning TD, Müller T, Hostetter D, Knopp C, Johansson M, Reinhart V, Boddington S, Sista A, Wels WS, Daldrup-Link HE (2009) Optical imaging of cellular immunotherapy against prostate cancer. Mol Imaging 8:15-26
15. Müller T, Uherek C, Maki G, Chow KU, Schimpf A, Klingemann HG, Tonn T, Wels WS (2008) Expression of a CD20-speciWc chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol Immunother 57:411-423. doi:10.1007/s00262- 007-0383-3 (Pubitemid 350295385)
16. Esser R, Müller T, Stefes D, Kloess S, Seidel D, Gillies SD, Aperlo-IZand C, Huston JS, Uherek C, Schönfeld K, Tonn T, Huebener N, Lode HN, Koehl U, Wels WS (2011) NK cells engineered to express a GD(2) -speciWc antigen receptor display built-in ADCClike activity against tumor cells of neuroectodermal origin. J Cell Mol Med (in press). doi:10.1111/j.1582-4934.2011. 01343.x
17. Maki G, Klingemann HG, Martinson JA, Tam YK (2001) Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92. J Hematother Stem Cell Res 10:369-383. doi:10.1089/152581601750288975 (Pubitemid 32673241)
18. Overwijk WW, Schluns KS (2009) Functions of gammaC cytokines in immune homeostasis: current and potential clinical applications. Clin Immunol 132:153-165. doi:10.1016/j.clim.2009. 03.512
19. Yamasaki S, Maeda M, Ohshima K, Kikuchi M, Otsuka T, Harada M (2004) Growth and apoptosis of human natural killer cell neoplasms: role of interleukin-2/15 signaling. Leuk Res 28:1023-1031 (Pubitemid 39037334)
20. Zhang J, Sun R, Wei H, Tian Z (2004) Characterization of interleukin-15 gene-modiWed human natural killer cells: implications for adoptive cellular immunotherapy. Haematologica 89:338-347 (Pubitemid 38788420)
21. Becknell B, Caligiuri MA (2005) Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv Immunol 86:209-239. doi:10.1016/S0065-2776(04)86006-1 (Pubitemid 40215694)
22. Robertson MJ, Cochran KJ, Cameron C, Le JM, Tantravahi R, Ritz J (1996) Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp Hematol 24:406-415 (Pubitemid 26098857)
23. Ball RK, Friis RR, Schoenenberger CA, Doppler W, Groner B (1988) Prolactin regulation of beta-casein gene expression and of a cytosolic 120-kd protein in a cloned mouse mammary epithelial cell line. EMBO J 7:2089-2095
24. Demaison C, Parsley K, Brouns G, Scherr M, Battmer K, Kinnon C, Grez M, Thrasher AJ (2002) High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeWciency virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 13:803-813. doi:10.1089/10430340252898984 (Pubitemid 34493974)
25. Willuda J, Honegger A, Waibel R, Schubiger PA, Stahel R, Zangemeister-Wittke U, Plückthun A (1999) High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment. Cancer Res 59:5758-5767
26. ZuVerey R, Nagy D, Mandel RJ, Naldini L, Trono D (1997) Multiply attenuated lentiviral vector achieves eYcient gene delivery in vivo. Nat Biotechnol 15:871-875. doi:10.1038/nbt0997-871
27. Zimmermann S, Wels W, Froesch BA, Gerstmayer B, Stahel RA, Zangemeister-Wittke U (1997) A novel immunotoxin recognising the epithelial glycoprotein-2 has potent antitumoural activity on chemotherapy-resistant lung cancer. Cancer Immunol Immunother 44:1-9 (Pubitemid 27135305)
28. Stonier SW, Schluns KS (2010) Trans-presentation: a novel mechanism regulating IL-15 delivery and responses. Immunol Lett 127:85-92
29. Boissel L, Betancur M, Wels WS, Tuncer H, Klingemann H (2009) Transfection with mRNA for CD19 speciWc chimeric antigen receptor restores NK cell mediated killing of CLL cells. Leuk Res 33:1255-1259. doi:10.1016/j. leukres.2008.11.024
30. Hoyos V, Savoldo B, Quintarelli C, Mahendravada A, Zhang M, Vera J, Heslop HE, Rooney CM, Brenner MK, Dotti G (2010) Engineering CD19-speciWc T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia eVects and safety. Leukemia 24:1160-1170. doi:10.1038/leu. 2010.75
31. Chmielewski M, Kopecky C, Hombach AA, Abken H (2011) IL-12 release by engineered T cells expressing chimeric antigen receptors can eVectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res 71:5697-5706. doi:10.1158/0008-5472. CAN-11-0103
32. Jiang W, Zhang J, Tian Z (2008) Functional characterization of interleukin-15 gene transduction into the human natural killer cell line NKL. Cytotherapy 10:265-274. doi:10.1080/1465324080 1965156 (Pubitemid 351566528)
33. Kurys G, Tagaya Y, Bamford R, Hanover JA, Waldmann TA (2000) The long signal peptide isoform and its alternative processing direct the intracellular traYcking of interleukin-15. J Biol Chem 275:30653-30659. doi:10.1074/jbc. M002373200
34. Bergamaschi C, Jalah R, Kulkarni V, Rosati M, Zhang GM, Alicea C, Zolotukhin AS, Felber BK, Pavlakis GN (2009) Secretion and biological activity of short signal peptide IL-15 is chaperoned by IL-15 receptor alpha in vivo. J Immunol 183:3064-3072
35. Browder TM, Abrams JS, Wong PM, Nienhuis AW (1989) Mechanism of autocrine stimulation in hematopoietic cells producing interleukin-3 after retrovirus-mediated gene transfer. Mol Cell Biol 9:204-213 (Pubitemid 19024792)
36. Konstantinidis KV, Alici E, Aints A, Christensson B, Ljunggren HG, Dilber MS (2005) Targeting IL-2 to the endoplasmic reticulum conWnes autocrine growth stimulation to NK-92 cells. Exp Hematol 33:159-164. doi:10.1016/j.exphem.2004. 11.003 (Pubitemid 40164897)
37. Hombach A, Wieczarkowiecz A, Marquardt T, Heuser C, Usai L, Pohl C, Seliger B, Abken H (2001) Tumor-speciWc T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for eYcient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J Immunol 167:6123-6131 (Pubitemid 33081538)
38. Munz M, Baeuerle PA, Gires O (2010) The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 69:5627-5629. doi:10.1158/0008-5472.CAN-09- 0654
39. van der Gun BT, Melchers LJ, Ruiters MH, de Leij LF, McLaughlin PM, Rots MG (2010) EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis 31:1913-1921. doi:10.1093/ carcin/bgq187
40. Tam YK, Miyagawa B, Ho VC, Klingemann HG (1999) Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J Hematother 8:281-290 (Pubitemid 29310062)